$DCOY News
Last published 1d ago
- 1d agoDCOYDecoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough AwardsGlobeNewswireRecognition highlights the IMP³ACT™ platform and Designable Multi-Antivirals (D-MAVs), single drugs designed to work across many viruses
- 1w agoDCOYDecoy Therapeutics Provides Third Quarter 2026 Business UpdateGlobeNewswireLead pan-coronavirus program expected to file CTA/IND in 2H 2027Optimized lead candidate shows potential for once-weekly dosing in preclinical studiesCash on balance sheet of $8.1 million at September 30, 2026
- 1mo agoDCOYDecoy Therapeutics Reports Preclinical Data Supporting Once-Weekly Intranasal Dosing for DCOY-CoV ProgramPR NewswireDecoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), today announced preclinical...
- 1mo agoDCOYDecoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press ReleasePR NewswireDecoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), today issued a correction to its press release dated September 22, 2026...
- 1mo agoDCOY/C O R R E C T I O N -- Decoy Therapeutics, Inc/PR NewswireDecoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™) to target major respiratory and...
- 1mo agoDCOYDecoy Therapeutics, Inc. Announces a Warrant Inducement Transaction for $3.85 Million in Gross Proceeds Priced At-The-Market under Nasdaq RulesPR NewswireDecoy Therapeutics, Inc. (NASDAQ: DCOY) ("the Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...
- 3mo agoDCOYDecoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ PlatformPR NewswireDecoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced continued expansion ...
- 3mo agoDCOYDecoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health ThreatsPR NewswireDecoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company developing Designable Multi-Antivirals (D-MAVs™), today announced that one of its...
- 3mo agoDCOYDecoy Therapeutics Stockholders Elect Patricia Gauthier to Board of DirectorsPR NewswireDecoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals...
- 4mo agoUPCDCOYVRDN4 Sizzling Biotech and Healthcare Companies Reporting Strategic MilestonesGlobeNewswireDENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives
- 4mo agoDCOYDecoy Therapeutics, Inc. Announces Up to $21 Million Private Placement FinancingPR NewswireDecoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...
- 5mo agoDCOYDecoy Therapeutics' CEO to Participate in hVIVO Capital Markets Day in LondonPR NewswireDecoy Therapeutics, Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals...
- 5mo agoDCOYDecoy Therapeutics Nominates Global Biopharma Executive Patricia Gauthier for Election to Board of DirectorsPR NewswireDecoy Therapeutics Inc. (Nasdaq: DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals...
- 5mo agoDCOYDecoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the ClinicPR NewswireDecoy Therapeutics Inc. (Nasdaq: DCOY), a pre-clinical-stage biotechnology company pioneering a new category of antivirals, today announced the...
- 5mo agoDCOYDecoy Therapeutics Names Brad Pentelute, MIT Professor of Chemistry, as Chair of Scientific Advisory BoardPR NewswireDecoy Therapeutics Inc. (Nasdaq: DCOY), a clinical-stage biotechnology company pioneering a new category of antivirals, today announced the...
- 6mo agoDCOYDecoy Therapeutics to Present at Two Peptide Therapeutics Conferences in BostonPR NewswireDecoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™), a new category...
- 7mo agoDCOYDecoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral PipelinePR NewswireDecoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...
- 7mo agoDCOYDecoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026PR NewswireDecoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...
- 7mo agoDCOYDecoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementPR NewswireDecoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), announces that on March 31, 2026 the Company received notification from the Nasdaq...
- 8mo agoDCOYDecoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation PlatformPR NewswireDecoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...
- 8mo agoDCOYDecoy Therapeutics Announces 1-for-12 Reverse Stock SplitPR NewswireDecoy Therapeutics Inc. (NASDAQ: DCOY), a preclinical-stage biopharmaceutical company that is engineering the next generation of peptide conjugate...
- 9mo agoDCOYDecoy Therapeutics Joins Webull Corporate Connect Service PlatformPR NewswireDecoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide...
- 9mo agoAIMAKTXBULLDCOY+2JTC Team Companies to Present in Webull Corporate Connect Webinar Series Happening February 10-11, 2026ACCESS NewswireRegister for the two-day virtual event hereFRENCHTOWN, NJ / ACCESS Newswire / February 9, 2026 / JTC Team , a fully integrated corporate communications and investor relations firm, today announced its companies
- 9mo agoDCOYDecoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull FinancialPR NewswireDecoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide...
- 9mo agoDCOYDecoy Therapeutics Participates in Virtual Investor "What This Means" Segment Highlighting Recently Announced Global Access Commitment AgreementPR NewswireDecoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide...
- 10mo agoDCOYDecoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing PlatformPR NewswireDecoy Therapeutics, Inc. (Nasdaq: DCOY) (Decoy, or the Company), a preclinical biopharmaceutical that is engineering the next generation of peptide...